Elanco Animal Health Incorporated (ELAN)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 3,273 | 4,764 | 4,411 | 4,417 | 4,439 | 4,715 | 5,020 | 5,130 |
| Operating profit | $m | 252 | 462 | ||||||
| Net profit | $m | -560 | -483 | -78 | -1,231 | 338 | -232 | -199 | 574 |
| EPS reported | $ | -0.47 | -0.40 | ||||||
| Operating cashflow per share | $ | 1.13 | 1.24 | ||||||
| Capex per share | $ | 0.56 | 0.48 | ||||||
| FCF per share | $ | 0.57 | 0.76 | ||||||
| Free cash flow | $m | 284 | 379 | ||||||
| Net debt | $m | 3,472 | 3,388 | ||||||
| Book value equity | $m | 6,547 | 6,588 | ||||||
| Book value per share | $ | 13.19 | 13.02 | ||||||
| Number of shares | m | 496.4 | 505.9 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.72 | 1.71 | ||||||
| P/S LTM | x | 2.38 | 2.24 | ||||||
| P/FCF LTM | x | 39.55 | 29.64 | ||||||
| EV/EBITDA LTM | x | 21.75 | 19.00 | ||||||
| EV/Sales LTM | x | 3.12 | 3.03 | ||||||
| Earnings Yield LTM | % | -2.07% | -1.68% | ||||||
| FCF Yield | % | +2.53% | +3.37% | ||||||
| Quality | |||||||||
| ROE | % | -3.54% | -3.02% | ||||||
| ROIC | % | +2.13% | +3.92% | ||||||
| Operating margin | % | +5.34% | +9.20% | ||||||
| Gross margin | % | +43.48% | +52.59% | ||||||
| FCF/Sales | % | +6.02% | +7.55% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +6.22% | +13.09% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | -27.92% | -3.81% | ||||||
| Operating Profit Growth | % | +0.40% | +84.06% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.07 | 0.10 | ||||||
| Net Debt/EBITDA | x | 5.14 | 4.38 | ||||||
| EBIT/Net interest | x | 1.15 | 1.78 | ||||||
| Net debt/market cap | % | +35.76% | +33.14% | ||||||
| Net debt/Equity | x | 0.53 | 0.51 | ||||||
| Gross debt/equity | x | 0.61 | 0.59 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Elanco Animal Health Incorporated (ELAN)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free